AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone, aimed at promoting lipolysis without the growth-promoting effects. Its primary application focuses on metabolic disorders and weight management, showing promise in enhancing fat oxidation and recovery in orthopedic and sports medicine. Despite favorable safety profiles, AOD-9604 remains unapproved for therapeutic use in major jurisdictions, necessitating further clinical trials to establish its efficacy.
subcutaneous, intramuscular
0.25-1.0 mg daily
2-4 hours
Refrigerated storage required
growth_hormone_receptors, adipocyte_receptors
AOD-9604 represents a synthetic peptide fragment derived from the C-terminal region of human growth hormone, specifically encompassing amino acids 176-191 . This 16-amino acid sequence was identified and developed as part of research efforts to isolate the lipolytic properties of growth hormone while eliminating its growth-promoting and diabetogenic effects .
growth_hormone_receptors
adipocyte_receptors
Research Use Only (RUO) - AOD-9604 Research Monograph: Overview and Applications is currently available for research purposes only and is not approved by regulatory agencies for human therapeutic use.
This report is generated for educational and informational purposes only. All research content is compiled from credible, peer-reviewed, and verified external scientific sources. This material does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making any decisions related to your health or treatment.
Discover the diverse applications and protocols of CJC-1295 in clinical practice. Learn about its mechanisms, benefits, and evidence-based guidelines for use.
April 26, 2026
Explore the mechanism of action of CJC-1295, a potent growth hormone-releasing hormone (GHRH) analog. Learn how it works to stimulate growth hormone release, its benefits, and scientific evidence supporting its use.
April 19, 2026